Cargando…

Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines

Sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) is a clinically investigated ruthenium-based metal complex, which shows promising results in solid tumors, such as non-small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors....

Descripción completa

Detalles Bibliográficos
Autores principales: Flocke, Lea S., Trondl, Robert, Jakupec, Michael A., Keppler, Bernhard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859864/
https://www.ncbi.nlm.nih.gov/pubmed/26988975
http://dx.doi.org/10.1007/s10637-016-0337-8
_version_ 1782431008575979520
author Flocke, Lea S.
Trondl, Robert
Jakupec, Michael A.
Keppler, Bernhard K.
author_facet Flocke, Lea S.
Trondl, Robert
Jakupec, Michael A.
Keppler, Bernhard K.
author_sort Flocke, Lea S.
collection PubMed
description Sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) is a clinically investigated ruthenium-based metal complex, which shows promising results in solid tumors, such as non-small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors. In previous studies, fast binding to albumin as well as transferrin could be shown. The enhanced permeability and retention (EPR) effect, which is diversely being exploited for tumor targeting, could therefore be applicable for NKP-1339. Here we studied the serum dependence of its biological activity in various methods, influencing its cellular accumulation, cytotoxicity as well as the generation of reactive oxygen species (ROS). ROS lead to Nrf2 activation, which is known to activate antioxidant response gene transcription. GRP78 down-regulation on the protein level suggests ER associated protein degradation (ERAD) as a mode of action, as RNA levels are only mildly affected. Another important part for the mode of action is endoplasmic reticulum (ER) stress, as different factors are highly upregulated on the protein level. For example PERK, a transmembrane receptor which is released by GRP78 when the ER is disturbed, is upregulated and phosphorylated. EIF2α is phosphorylated, which leads to an inhibition of CAP-dependent translation and other stress responses. The transcription factor CHOP (DDIT3), which promotes ER stress dependent apoptosis, is time and concentration dependently upregulated. Finally cytotoxicity tests could prove that inhibition of ER stress and ER stress-mediated apoptosis leads to decreased cytotoxic effects of NKP-1339, which highlights the involvement of this mechanism in the mode of action. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10637-016-0337-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4859864
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-48598642016-05-21 Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines Flocke, Lea S. Trondl, Robert Jakupec, Michael A. Keppler, Bernhard K. Invest New Drugs Preclinical Studies Sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) is a clinically investigated ruthenium-based metal complex, which shows promising results in solid tumors, such as non-small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors. In previous studies, fast binding to albumin as well as transferrin could be shown. The enhanced permeability and retention (EPR) effect, which is diversely being exploited for tumor targeting, could therefore be applicable for NKP-1339. Here we studied the serum dependence of its biological activity in various methods, influencing its cellular accumulation, cytotoxicity as well as the generation of reactive oxygen species (ROS). ROS lead to Nrf2 activation, which is known to activate antioxidant response gene transcription. GRP78 down-regulation on the protein level suggests ER associated protein degradation (ERAD) as a mode of action, as RNA levels are only mildly affected. Another important part for the mode of action is endoplasmic reticulum (ER) stress, as different factors are highly upregulated on the protein level. For example PERK, a transmembrane receptor which is released by GRP78 when the ER is disturbed, is upregulated and phosphorylated. EIF2α is phosphorylated, which leads to an inhibition of CAP-dependent translation and other stress responses. The transcription factor CHOP (DDIT3), which promotes ER stress dependent apoptosis, is time and concentration dependently upregulated. Finally cytotoxicity tests could prove that inhibition of ER stress and ER stress-mediated apoptosis leads to decreased cytotoxic effects of NKP-1339, which highlights the involvement of this mechanism in the mode of action. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10637-016-0337-8) contains supplementary material, which is available to authorized users. Springer US 2016-03-18 2016 /pmc/articles/PMC4859864/ /pubmed/26988975 http://dx.doi.org/10.1007/s10637-016-0337-8 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Preclinical Studies
Flocke, Lea S.
Trondl, Robert
Jakupec, Michael A.
Keppler, Bernhard K.
Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
title Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
title_full Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
title_fullStr Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
title_full_unstemmed Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
title_short Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
title_sort molecular mode of action of nkp-1339 – a clinically investigated ruthenium-based drug – involves er- and ros-related effects in colon carcinoma cell lines
topic Preclinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859864/
https://www.ncbi.nlm.nih.gov/pubmed/26988975
http://dx.doi.org/10.1007/s10637-016-0337-8
work_keys_str_mv AT flockeleas molecularmodeofactionofnkp1339aclinicallyinvestigatedrutheniumbaseddruginvolveserandrosrelatedeffectsincoloncarcinomacelllines
AT trondlrobert molecularmodeofactionofnkp1339aclinicallyinvestigatedrutheniumbaseddruginvolveserandrosrelatedeffectsincoloncarcinomacelllines
AT jakupecmichaela molecularmodeofactionofnkp1339aclinicallyinvestigatedrutheniumbaseddruginvolveserandrosrelatedeffectsincoloncarcinomacelllines
AT kepplerbernhardk molecularmodeofactionofnkp1339aclinicallyinvestigatedrutheniumbaseddruginvolveserandrosrelatedeffectsincoloncarcinomacelllines